{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:44:12Z","timestamp":1770511452108,"version":"3.49.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.oftal.2013.07.007","type":"journal-article","created":{"date-parts":[[2013,10,7]],"date-time":"2013-10-07T23:00:22Z","timestamp":1381186822000},"page":"473-481","source":"Crossref","is-referenced-by-count":4,"title":["Cambios en la morfolog\u00eda y la microdensidad neovascular corneal inducidos tras la administraci\u00f3n t\u00f3pica de bevacizumab y sunitinib en un modelo animal"],"prefix":"10.1016","volume":"88","author":[{"given":"J.J.","family":"P\u00e9rez-Santonja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Campos-Mollo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lled\u00f3-Riquelme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Fern\u00e1ndez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Cuenca-Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oftal.2013.07.007_bib0005","first-page":"264","article-title":"Corneal angiogenic privilege: Angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American ophthalmological society thesis)","volume":"104","author":"Azar","year":"2006","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.oftal.2013.07.007_bib0010","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/00003226-199811000-00008","article-title":"Angiogenesis in corneal diseases: Histopathologic evaluation of 254 human corneal buttons with neovascularization","volume":"17","author":"Cursiefen","year":"1998","journal-title":"Cornea"},{"key":"10.1016\/j.oftal.2013.07.007_bib0015","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.oftal.2013.07.007_bib0020","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1167\/iovs.06-0570","article-title":"Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis","volume":"48","author":"Bock","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oftal.2013.07.007_bib0025","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":"Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)","volume":"91","author":"Manzano","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oftal.2013.07.007_bib0030","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","article-title":"Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization","volume":"247","author":"Koenig","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oftal.2013.07.007_bib0035","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0420.2007.01049.x","article-title":"Safety, penetration and efficacy of topically applied bevacizumab: Evaluation of eyedrops in corneal neovascularization after chemical burn","volume":"86","author":"Yoeruek","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oftal.2013.07.007_bib0040","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ajo.2007.11.003","article-title":"Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model","volume":"145","author":"Papathanassiou","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oftal.2013.07.007_bib0045","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2353\/ajpath.2006.050588","article-title":"Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization","volume":"168","author":"Jo","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.oftal.2013.07.007_bib0050","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ajo.2010.04.024","article-title":"Inhibition of corneal neovascularization by topical bevacizumab (anti-VEGF) and sunitinib (anti-VEGF and anti-PDGF) in an animal model","volume":"150","author":"P\u00e9rez-Santonja","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oftal.2013.07.007_bib0055","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000319749","article-title":"New corneal neovascularization model in rabbits for angiogenesis research","volume":"45","author":"Campos-Mollo","year":"2011","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.oftal.2013.07.007_bib0060","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00417-007-0683-5","article-title":"Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation","volume":"246","author":"Bock","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oftal.2013.07.007_bib0065","first-page":"2514","article-title":"Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas","volume":"41","author":"Philipp","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oftal.2013.07.007_bib0070","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1006\/exer.1999.0790","article-title":"Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization","volume":"70","author":"Kvanta","year":"2000","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.oftal.2013.07.007_bib0075","first-page":"18","article-title":"Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization","volume":"39","author":"Amano","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oftal.2013.07.007_bib0080","first-page":"1112","article-title":"Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea","volume":"40","author":"Edelman","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oftal.2013.07.007_bib0085","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bbrc.2007.02.156","article-title":"Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor","volume":"356","author":"Roskoski","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.oftal.2013.07.007_bib0090","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/OPTH.S5156","article-title":"Age-related macular degeneration: Experimental and emerging treatments","volume":"3","author":"Hubschman","year":"2009","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oftal.2013.07.007_bib0095","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.oftal.2013.07.007_bib0100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/jop.2006.22.213","article-title":"A novel vascular endothelial growth factor receptor 2 inhibitor, SU11248, suppresses choroidal neovascularization in vivo","volume":"22","author":"Takahashi","year":"2006","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365669113002839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365669113002839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T10:21:41Z","timestamp":1539339701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365669113002839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0365669113002839"],"URL":"https:\/\/doi.org\/10.1016\/j.oftal.2013.07.007","relation":{},"ISSN":["0365-6691"],"issn-type":[{"value":"0365-6691","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}